Marijn Dekkers will have a base salary of $1.165 million under a new agreement with Thermo Fisher Scientific, according to a document filed with the US Securities and Exchange Commission last week.
The contract, which runs through the end of 2017, also provides Dekker, the president and CEO of the firm, a target incentive bonus of 125 percent of his base salary.
In 2007, Dekkers made $10.48 million in total, down 2.2 percent from $10.71 million in 2006. His base salary for 2007 was $1.125 million, compared to $1 million in 2006. His bonus shrunk to $1.93 million from $2.14 million and his stock awards slid to $1.39 million in 2007 from $2.60 million in 2006.
Danong Chen has been elected president and CEO of Theranostics Health, the company announced this week.
Chen was previously president and CEO of Tanox, which was acquired by Genentech in 2007. She also had served as vice president of strategy and corporate development at Tanox
Theranostics is a protein microarray company founded in 2007 by Lance Liotta and Emanuel Petricoin [see PM 03/29/07]. Its core technology is the Reverse Phase Protein Microarray, which measures biomarker activity.
Stephan Frost has joined Miraculins as the director of R&D, the company said this week. He had been a consultant for the company since January.
Prior to joining Miraculins, Frost was at Abbott Laboratories Diagnostics Division for 15 years, where he evaluated oncology assays for license or acquisition. He was also the project manager for several “high-profile” cancer-related projects. Before Abbott, he was a research associate for NASA.
Vermillion last week announced the appointment of John Hamilton to its board. He replaces Judy Bruner, executive vice president of administration and CFO of SanDisk, who resigned.
Hamilton is the former vice president and chief financial officer of Depomed, a specialty pharmaceutical firm.
He also held senior management positions at Glyko, now called BioMarin Pharmaceuticals, and Chiron. He currently is on the regional board of directors of the Association of Bioscience Financial Officers.
Hamilton will also serve as chair of Vermillion’s audit committee.
Calibrant Biosystems appointed Satya Saxena vice president of R&D this week to lead the company’s proteomic technology and product development programs.
His primary focus will be to expand and validate Calibrant’s Gemini platform technology beyond the initial oncology programs, the company said in a statement. He also will oversee the continuing drug development efforts involving lead compounds in ovarian, breast, and brain cancer.
He was previously at the NIH’s National Institute on Aging, where he oversaw the development of proteomic technologies.
Phase Bioscience this week named Christopher Prior its CEO and a board member.
Prior to joining Phase, Prior was founder, president, and CSO of BioRexis Pharmaceuticals, which Pfizer acquired in 2007. He was also founder and president of Principia Pharmaceuticals and a senior executive at Human Genome Sciences, after its purchase of Principia.
Based in Research Triangle Park, NC, Phase is a protein engineering firm. Its technology is based on polymers of elastin-like repeating subunits to which peptides and proteins can be fused, or drugs can be attached.